Taida, Takashi
Ohta, Yuki
Kato, Jun
Ogasawara, Sadahisa
Ohyama, Yuhei
Mamiya, Yukiyo
Nakazawa, Hayato
Horio, Ryosuke
Goto, Chihiro
Takahashi, Satsuki
Kurosugi, Akane
Sonoda, Michiko
Shiratori, Wataru
Kaneko, Tatsuya
Yokoyama, Yuya
Akizue, Naoki
Iino, Yotaro
Kumagai, Junichiro
Ishigami, Hideaki
Koseki, Hirotaka
Okimoto, Kenichiro
Saito, Keiko
Saito, Masaya
Matsumura, Tomoaki
Nakagawa, Tomoo
Okabe, Shinichiro
Saito, Hirofumi
Kato, Kazuki
Uehara, Hirotsugu
Mizumoto, Hideaki
Koma, Yoshihiro
Azemoto, Ryosaku
Ito, Kenji
Kamezaki, Hidehiro
Mandai, Yoshifumi
Masuya, Yoshio
Fukuda, Yoshihiro
Kitsukawa, Yoshio
Shimura, Haruhisa
Tsuyuguchi, Toshio
Kato, Naoya
Funding for this research was provided by:
Public Incorporated Foundation Tsuchiya Bunka Shinkou Zaidan, Japan.
Article History
Received: 7 November 2022
Accepted: 14 August 2023
First Online: 21 August 2023
Competing interests
: Sadahisa Ogasawara received honoraria from Eisai Co., Ltd., Takeda Pharmaceutical Co., Ltd., Abbvie G.K.; consulting or advisory fees from Eisai Co., Ltd., and research grants from Eisai Co., Ltd.. Naoya Kato received honoraria from AbbVie G.K., Ohtsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Zeria Pharmaceutical Co., Ltd., Olympus Corporation, Eisai Co., Ltd., Tsumura & Co., Mochida Pharmaceutical Co., Ltd., Miyarisan Pharmaceutical Co., Ltd., Yakult Honsha Co., Ltd., Olympus Marketing, Inc., and Janssen Pharmaceutical K.K., and research funding from Ohtsuka Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Eisai Co., Ltd., Tsumura & Co., Nippon Kayaku Co., Ltd., and JIMRO Co., Ltd. The other authors have no conflicts of interest to declare.